Subscribe to our newsletter and stay informed
In a groundbreaking move, Belgian clinical biotech company PDC*line Pharma, in collaboration with strategic partners, has announced a significant funding injection to propel the development of a revolutionary personalized therapeutic vaccine targeting neoantigens for colorectal cancer.
This week marks a pivotal moment in the fight against colorectal cancer as PDC*line Pharma, a Belgian-French clinical-stage biotech pioneer, unveils ambitious plans for a groundbreaking therapeutic vaccine. The collaborative effort aims to revolutionize cancer treatment and pave the way for a more personalized and effective approach.
At the heart of this endeavor is the development of PDC*neo+, a cutting-edge personalized therapeutic vaccine designed to act as an adjuvant treatment for colorectal cancer. With a focus on preventing relapses in high-risk patients at stages II, III, and specific stage IV colorectal cancers, the project represents a beacon of hope in addressing the challenges of post-surgery and post-chemotherapy recurrence.
The project's success hinges on the collaboration of key players, including OncoDNA, salamanderU i, and esteemed academic centers UCLouvain – IREC and ULB-BCTL. This formidable consortium is set to receive €8.1 million in funding, with PDC*line Pharma securing a significant €4.7 million portion. The total budget for this groundbreaking initiative is an impressive €12.5 million.
Over the course of three years, the project anticipates creating and sustaining approximately 34 full-time jobs across all partner organizations. This not only underscores the significance of the initiative but also highlights its potential to contribute to economic growth and job creation.
As a testament to its commitment to innovation, PDC*line Pharma has already raised over €61 million in equity and non-dilutive funding. The company's previous ventures, including a strategic license granted to LG Chem Life Sciences for the PDC*lung01 cancer vaccine, position it as a frontrunner in the field.
Eric Halioua, CEO of PDC*line Pharma, expressed profound optimism about the project, stating, "We are very happy that the Walloon region has selected our project. The subsidies and collaborative effort of the partners in the consortium will speed up the launch of a first phase I clinical trial with PDC*neo+, positioning our technology in the very promising field of neoantigen-based cancer vaccines."
In the relentless pursuit of innovative cancer therapies, PDC*line Pharma's latest venture offers a glimpse into the future of personalized medicine for colorectal cancer. With substantial funding, visionary collaborations, and a commitment to transformative cancer care, this initiative holds the promise of reshaping the landscape of colorectal cancer treatment.
